While weight-loss drugs were linked to lower risk of some conditions, they were also associated with some adverse health outcomes. Blockbuster weight loss drugs can help treat ailments as disparate as addiction, blood clotting, and dementia – but they also come with risks that might give some patients pause, a landmark new study has found.
The analysis used data from more than two million diabetes patients in the United States, including about 216,000 taking the popular drugs, to map out their risks and benefits across 175 possible health outcomes.
Wegovy, Ozempic, Zepbound, and related medicines belong to a class of drugs known as GLP-1 receptor agonists, which are diagnosed for obesity or type 2 diabetes and work by suppressing people’s appetites to help them lose weight.
But the medicines are also linked to a lower risk of drug and alcohol addiction, psychotic disorders such as schizophrenia, seizures, blood clotting problems, infections, several respiratory issues, chronic kidney disease, and neurocognitive disorders, according to the study, which was published in the journal Nature Medicine.
SOURCE: EURONEWS
